General
Preferred name
physostigmine
Synonyms
PHYSOSTIGMINE SULFATE ()
PHYSOSTIGMINE SALICYLATE ()
(-)-Physostigmine ()
Eserine sulfate, physostigmine sulfate ()
Eserine hemisulfate salt ()
Physostigmine (salicylate) ()
Eserine (salicylate) ()
Physostigmine hemisulfate ()
Eserinum ()
MCV-4484 ()
Eserin ()
NSC-30782 ()
Eserine ()
Cogmine ()
Physostigmini salicylas ()
Eserine Salicylate ()
Isopto Eserine ()
NSC-757275 ()
Physostigmine monosalicylate ()
Antilirium ()
Physostigmine sulphate ()
Physostigmine sulfate (2:1) ()
Physostigmine sulphate (2:1) ()
Eserine Sulfate ()
(?)-Physostigmine (salicylate) ()
P&D ID
PD001599
CAS
57-47-6
57-64-7
11033-04-8
11036-67-2
50975-37-6
64-47-1
Tags
covalent binder
natural product
drug
available
First approval
1875
Drug Status
investigational
approved
Drug indication
Xerostomia
Cholinergic (ophthalmic)
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Physostigmine, originally isolated from the Calabar bean, is a parasympathomimetic alkaloid, acting as a reversible cholinesterase inhibitor (the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft of the neuromuscular junction). (GtoPdb)
DESCRIPTION Cholinesterase inhibitor (LOPAC library)
DESCRIPTION Physostigmine hemisulfate, a derivative of Physostigmine, is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
26
BOC Sciences Bioactive Compounds
physostigmine-hemisulfate-cas-64-47-1-item-31008
Cayman Chemical Bioactives
33106
ChEMBL Approved Drugs
CHEMBL94
CHEMBL338975
CHEMBL2105891
ChEMBL Drugs
CHEMBL94
CHEMBL338975
CHEMBL2105891
Concise Guide to Pharmacology 2017/18
6598
Concise Guide to Pharmacology 2019/20
6598
Concise Guide to Pharmacology 2021/22
6598
Concise Guide to Pharmacology 2023/24
6598
CovalentInDB
CI002082
Drug Repurposing Hub
DrugBank
DB00981
DrugBank Approved Drugs
DB00981
DrugCentral
2159
DrugCentral Approved Drugs
2159
DrugMAP
DM2N0TO
Guide to Pharmacology
6598
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL94
MedChem Express Bioactive Compound Library
HY-B1266
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T0130
The Spectrum Collection
ZINC Tool Compounds
ZINC000091689892
External IDs
87
Properties
(calculated by RDKit )
Molecular Weight
275.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
1.77
TPSA
44.81
Fraction CSP3
0.53
Chiral centers
2.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Cholinesterase
Pathway
Neuroscience
Neuronal Signaling
Target
AChR
ACHE, BCHE
Cholinesterase (ChE)
Indication
hypotension, Alzheimer's disease, glaucoma, gastroparesis
Disease Area
cardiology, neurology/psychiatry, ophthalmology, gastroenterology
MOA
acetylcholinesterase inhibitor, cholinesterase inhibitor
Solubility
DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
Source data